Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Y

24.03.2022 - -Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial collaboration with Merck for WTX-124 INDUKINETM program- -Reported positive preclinical data at SITC demonstrating the potential to drive targeted ...

Related Keywords

Canada , United States , Cambridge , Cambridgeshire , United Kingdom , American , Randi Isaacs , Ameeta Chatterjee , Chulani Karunatilake , Ellen Lubman , Danielj Hicklin , Jonathanm Nugent , Mike Sherman , Company Board Of Directors , Company Contact , Company Or Werewolf Nasdaq , Nasdaq , Scientific Communications , American Society Of Hematology , Exchange Commission , Stern Ir Inc , Technology Officer , Werewolf Therapeutics Inc , Chief Executive Officer , Initial Public Offering , Annual Meeting , American Society , Two Industry Leaders , Operations Teams , Chief Technology , Manufacturing Controls , Nasdaq Biotechnology Index , Nasdaq Biotechnology , Nasdaq Stock Market , Industry Classification , Fourth Quarter , Full Year , Werewolf Therapeutics , Private Securities Litigation Reform Act , Consolidated Statements , Condensed Consolidated Balance Sheet Data ,